Table 1.
Baseline demography and characteristics of included studies.
| Author (year) | RCT Name | Trial Population (n) | Intervention (n) | Control (n) | Age Mean (S.D) & Gender (M/F) | Baseline NYHA class (n) | Baseline KCCQ CSS Score; Mean (SD) | Follow-up Duration (weeks) | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Intervention | Placebo | Intervention | Placebo | |||||||
| CAROLYN (2020) | MAVERICK-HCM | 59 Non obstructive HCM | 19 with mavacamten 200 ng/dl 21 with mavacamten 500 ng/dl |
19; Placebo | 53.8 (16.0) & (25/34) | 33 class II7 class III | 13 class II6 class III | NA | 16 weeks for echo outcomes,24 weeks for TAEs, SAEs, and Afib | |
| DESAI (2022) | VALOR-HCM | 112 obstructive HCM patients | 56; Mavacamten 2.5, 5, 10 or 15 mg | 56; Placebo | 60.35 (12.5) & (57/55) | 4 class II, 53 class III or higher | 4 class II52 class III or higher | 69.5(16.3) | 45.9(19.9) | 16 week |
| OLIVOTTO (2020) | EXPLORER-HCM | 251 obstructive HCM patients | 123; Mavacamten 2.5, 5, 10, or 15 mg | 128; Placebo | 58.5(11.1) & (149/103) | 88 class II,35 class III | 95 class II33 class III | NA | 30 week | |
| ZHUANG TIAN (2021) | EXPLORER-CN | 81 obstructive HCM patients | 54; Mavacamten 1,2.5,5,10 or 15 mg |
27; Placebo | 51.9 (12.0) & (58/23) | 44 class II, 10 class III/ | 18 class II9 class III / | 82.4(16.9) | 16 week | |
Abbreviations: RCT: Randomized Controlled Trial; HCM: Hypertrophic Cardiomyopathy; NYHA:New York Heart Association; KCCQ-CSS: Kansas City Cardiomyopathy Questionnaire.